GSA Capital Partners LLP Acquires 109,240 Shares of Accelerate Diagnostics, Inc. (NASDAQ:AXDX)

GSA Capital Partners LLP boosted its holdings in Accelerate Diagnostics, Inc. (NASDAQ:AXDXGet Rating) by 206.7% in the 1st quarter, HoldingsChannel.com reports. The firm owned 162,081 shares of the medical research company’s stock after purchasing an additional 109,240 shares during the period. GSA Capital Partners LLP’s holdings in Accelerate Diagnostics were worth $233,000 at the end of the most recent quarter.

Other hedge funds have also added to or reduced their stakes in the company. New York State Common Retirement Fund lifted its stake in Accelerate Diagnostics by 96.9% in the fourth quarter. New York State Common Retirement Fund now owns 15,649 shares of the medical research company’s stock worth $82,000 after purchasing an additional 7,701 shares during the last quarter. Keebeck Alpha LP lifted its stake in Accelerate Diagnostics by 90.9% in the fourth quarter. Keebeck Alpha LP now owns 21,731 shares of the medical research company’s stock worth $113,000 after purchasing an additional 10,349 shares during the last quarter. Swiss National Bank lifted its stake in Accelerate Diagnostics by 19.0% in the first quarter. Swiss National Bank now owns 85,300 shares of the medical research company’s stock worth $123,000 after purchasing an additional 13,600 shares during the last quarter. Allworth Financial LP lifted its stake in Accelerate Diagnostics by 104.0% in the first quarter. Allworth Financial LP now owns 102,000 shares of the medical research company’s stock worth $147,000 after purchasing an additional 52,000 shares during the last quarter. Finally, Belpointe Asset Management LLC raised its stake in shares of Accelerate Diagnostics by 12.0% during the first quarter. Belpointe Asset Management LLC now owns 187,984 shares of the medical research company’s stock valued at $271,000 after acquiring an additional 20,157 shares during the last quarter. 23.20% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

AXDX has been the subject of several recent analyst reports. Craig Hallum lowered their price objective on shares of Accelerate Diagnostics to $1.00 and set an “underperform” rating for the company in a research note on Tuesday, May 17th. StockNews.com downgraded shares of Accelerate Diagnostics from a “hold” rating to a “sell” rating in a research note on Saturday, June 4th.

Accelerate Diagnostics Price Performance

Shares of NASDAQ AXDX opened at $1.63 on Thursday. Accelerate Diagnostics, Inc. has a 1 year low of $0.50 and a 1 year high of $7.19. The company’s 50-day moving average is $1.55 and its 200 day moving average is $1.41. The stock has a market capitalization of $132.94 million, a P/E ratio of -1.75 and a beta of 1.51.

Accelerate Diagnostics (NASDAQ:AXDXGet Rating) last announced its quarterly earnings results on Monday, August 15th. The medical research company reported ($0.23) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.28) by $0.05. During the same quarter in the previous year, the firm posted ($0.36) EPS.

Insider Activity at Accelerate Diagnostics

In related news, CEO Jack Phillips sold 28,198 shares of the business’s stock in a transaction dated Wednesday, June 22nd. The shares were sold at an average price of $0.91, for a total transaction of $25,660.18. Following the transaction, the chief executive officer now owns 242,035 shares in the company, valued at $220,251.85. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. In other Accelerate Diagnostics news, CEO Jack Phillips sold 28,198 shares of the company’s stock in a transaction dated Wednesday, June 22nd. The shares were sold at an average price of $0.91, for a total value of $25,660.18. Following the sale, the chief executive officer now owns 242,035 shares in the company, valued at $220,251.85. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, CTO Larry Michael Mertz acquired 50,000 shares of the business’s stock in a transaction on Tuesday, August 30th. The stock was acquired at an average price of $1.60 per share, for a total transaction of $80,000.00. Following the acquisition, the chief technology officer now owns 433,411 shares of the company’s stock, valued at approximately $693,457.60. The disclosure for this purchase can be found here. Insiders have purchased 106,749 shares of company stock worth $156,811 over the last 90 days. 42.20% of the stock is owned by company insiders.

Accelerate Diagnostics Profile

(Get Rating)

Accelerate Diagnostics, Inc, an in vitro diagnostics company, provides solutions for the diagnosis of serious infections in the United States, Europe, and the Middle East. The company offers Accelerate Pheno system, an in vitro diagnostic platform for the identification and antibiotic susceptibility testing of pathogens associated with serious or health care-associated infections, including gram-positive and gram-negative organisms.

Featured Stories

Want to see what other hedge funds are holding AXDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Accelerate Diagnostics, Inc. (NASDAQ:AXDXGet Rating).

Institutional Ownership by Quarter for Accelerate Diagnostics (NASDAQ:AXDX)

Receive News & Ratings for Accelerate Diagnostics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Accelerate Diagnostics and related companies with MarketBeat.com's FREE daily email newsletter.